Literature DB >> 11408955

Unchanged frequency of loss of heterozygosity and size of the deleted region at 8p21-23 during metastasis of lung cancer.

F Kurimoto1, A Gemma, Y Hosoya, M Seike, K Takenaka, K Uematsu, A Yoshimura, M Shibuya, S Kudoh.   

Abstract

The genetic mechanisms involved in lung cancer development and progression are beginning to be understood. Many studies have documented frequent loss of heterozygosity (LOH) at specific chromosomal regions in cancer cells; this implies that tumor suppressor genes (TSG) are usually present in those regions. Recently, it has been reported that LOH or chromosomal deletions at chromosome 8p21-23 represent early events frequently occurring in lung cancer. In addition, the size of these chromosome 8 deletions, as well as their frequency, was also reported to increase during lung cancer progression. To determine the spectrum and frequency of alterations of chromosome 8p21-23 in human lung cancer and whether these increase with progression of the tumors, we performed LOH analysis of chromosome 8p and 3p in the genomic DNA from cells from primary and metastatic sites of lung cancer, as well as from normal lung. We studied 35 subjects with primary lung cancer including 30 tumors with distant metastasis. Detection of allelic deletion utilized a PCR-based approach of microsatellite polymorphism analysis, which was performed using the microsatellite markers D8S1130, D8S1106, D8S511, D8S1827, D8S549, D8S261, LPL, D8S258, D8S136, NEFL, D3S1295, D3S1313, D3S1234, D3S1300, D3S1351, D3S1339, and D3S1340. The overall allelic deletion rates were 10 of 28 (35.7%) at 8p and 13 of 33 (39.4%) at 3p. The allelic deletions in the primary cancer and its metastatic sites were in each case identical in both frequency and size of the deleted regions. In our analysis, 8p21-23 deletions were not always associated with 3p deletions in primary lung cancer. These results therefore suggest that allelic deletion at chromosome 8p21-23 is an early and frequent event in the carcinogenesis and development of lung cancer, independent of chromosome 3p deletion. However, a continuing increase in the frequency of LOH at 8p21-23 and in the size of the deleted region rarely occurs during the process of metastasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408955     DOI: 10.3892/ijmm.8.1.89

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

1.  CSR1 induces cell death through inactivation of CPSF3.

Authors:  Z-H Zhu; Y P Yu; Y-K Shi; J B Nelson; J-H Luo
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

2.  NF-κB and cancer: a paradigm of Yin-Yang.

Authors:  Gutian Xiao; Jing Fu
Journal:  Am J Cancer Res       Date:  2010-12-06       Impact factor: 6.166

3.  Interaction of CSR1 with XIAP reverses inhibition of caspases and accelerates cell death.

Authors:  Zhong-Liang Zheng; Lang-Zhu Tan; Yan P Yu; George Michalopoulos; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2012-06-08       Impact factor: 4.307

4.  NK3 homeobox 1 (NKX3.1) up-regulates forkhead box O1 expression in hepatocellular carcinoma and thereby suppresses tumor proliferation and invasion.

Authors:  Jingyi Jiang; Zheng Liu; Chao Ge; Cong Chen; Fangyu Zhao; Hong Li; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

5.  NEFL mRNA expression level is a prognostic factor for early-stage breast cancer patients.

Authors:  Xiao-Qing Li; Lin Li; Chun-Hua Xiao; Yu-Mei Feng
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

6.  Genomic alterations on 8p21-p23 are the most frequent genetic events in stage I squamous cell carcinoma of the lung.

Authors:  Jiun Kang
Journal:  Exp Ther Med       Date:  2014-12-09       Impact factor: 2.447

7.  Association between NEFL Gene Polymorphisms and Neuroblastoma Risk in Chinese Children: A Two-Center Case-Control Study.

Authors:  Qiang Wu; Zhen-Jian Zhuo; Jixiao Zeng; Jiao Zhang; Jinhong Zhu; Yan Zou; Ruizhong Zhang; Tianyou Yang; Deli Zhu; Jing He; Huimin Xia
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.